Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Edge Therapeutics Inc (NASDAQ:EDGE)

10.38
Delayed Data
As of 3:59pm ET
 -0.15 / -1.42%
Today’s Change
7.30
Today|||52-Week Range
13.50
-16.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$324.9M

Company Description

Edge Therapeutics, Inc. operates as biotechnology company which develops therapies. engages in the discovery, development, and commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions for which limited or no current therapies exist. It develops the Precisa Platform of EG-1962 and the EG-1964 treatments. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Contact Information

Edge Therapeutics, Inc.
300 Connell Drive
Berkeley Heights New Jersey 07922
P:(800) 208-3343
Investor Relations:

Employees

Shareholders

Individual stakeholders31.98%
Mutual fund holders23.32%
Other institutional20.26%

Top Executives

Brian A. LeuthnerPresident, Chief Executive Officer & Director
Daniel BrennanChief Operating Officer
Albert N. MarchioCFO, Chief Accounting & Administrative Officer
Robert Loch MacdonaldDirector & Chief Scientific Officer
Herbert J. FaleckChief Medical Officer